Quinaks® (Quinax®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceAzazentaleneAzazentalene
Similar drugsTo uncover
  • Quinaks®
    drops d / eye 
    Alkon-Kouvreur N.V. S.A.     Belgium
    • Dosage form: & nbspeye drops
    Composition:

    Composition 1 ml of the preparation

    Active substance: dihydroazapentaienne sodium polysulfonate 0.15 mg;

    Excipients: boric acid 6.30 mg; sodium borate 0.30 mg; potassium chloride 7.15 mg; methylparahydroxybenzoate 0.065 mg; propyl parahydroxybenzoate 0.035 mg; thiomersal 0.002 mg; sodium hydroxide and / or hydrochloric acid concentrated to pH adjustment; water purified to 1.0 ml.

    Description:

    Transparent solution from red-pink to red-magenta.

    Pharmacotherapeutic group:Cataract treatment
    ATX: & nbsp

    S.01.X   Other drugs for the treatment of eye diseases

    Pharmacodynamics:

    Azadentacene inhibits the action of quinoidic substances formed as a result of metabolic disturbances of aromatic amino acids, protecting the sulfhydryl groups of soluble proteins from the lens from oxidation and further degradation; activates proteolytic enzymes contained in the aqueous fluid of the anterior chamber of the eye.

    Pharmacokinetics:

    With topical application, systemic absorption is low.

    Indications:

    Cataracts:

    - senile;

    - traumatic;

    - congenital;

    - secondary.

    Contraindications:

    Hypersensitivity to the components of the drug.

    Pregnancy and lactation:

    Fertility

    Studies on the evaluation of the effect of azadaptacene preparations for local ophthalmic use on fertility have not been conducted.

    Pregnancy

    Data on the use of azadaptacene preparations for local ophthalmic use in pregnant women are either not available or limited.

    The use of the drug Kvinaks ® for the treatment of pregnant women is possible only for the purpose of the attending physician, if the expected curative effect exceeds the risk of development of possible side effects. Breastfeeding period It is currently unknown whether azadacentar and / or metabolites with human breast milk after topical ophthalmic use, but the risk to a breastfeeding child can not be ruled out.

    It is not recommended to use the drug when breastfeeding.

    Dosing and Administration:

    Locally. 2 drops in the conjunctival sac of the eye 3-5 times a day.

    Side effects:

    During post-marketing surveillance after application of azapentacene for ophthalmic use, the following undesirable reactions were identified (frequency unknown).

    Disturbances on the part of the organ of sight

    Pain in the eyes, eye irritation, lacrimation, conjunctival injection, allergic reactions, discomfort in the eye area, dry eye syndrome.

    Overdose:

    With topical application of the drug, an overdose is unlikely. If eye contact is excessive, it is recommended to wash eyes with warm water.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    Quinaks® is intended for long-term therapy. It is not recommended to interrupt treatment even in case of rapid improvement.

    Quinax® is not intended for the therapy of cataract stages, in which surgical intervention is required.

    For patients using contact lenses, before using the drug, the lenses should be removed and placed back no earlier than 15 minutes after instillation of the drug.

    Quinax® contains thiomersal (mercury-organic matter) as a preservative and can cause allergic reactions.

    The preparation also contains methyl parahydroxybenzoate and propyl parahydroxybenzoate as preservatives, which can also cause allergic reactions (possibly, delayed-type reactions). The bottle must be closed after each use.Do not touch the tip of the pipette with any surfaces.

    Effect on the ability to drive transp. cf. and fur:
    Temporary blurring of vision or other visual impairment after application of the drug may affect the ability to drive a car or use mechanisms. If blurring of vision occurs after instillation of the drug, then before driving a vehicle or controlling the mechanisms, the patient must wait for the restoration of the clearness of vision.
    Form release / dosage:

    Eye drops 0.015%.

    Packaging:15 ml per bottle-dropper "Droptainer™" from low density polyethylene. For 1 bottle with instructions for use in a pack of cardboard.
    Storage conditions:

    Store at a temperature of 2 to 8 ° C in a dark place.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Use within 4 weeks after opening the vial.

    Do not use after the expiry date printed on the package!

    Terms of leave from pharmacies:On prescription
    Registration number:П N014809 / 01
    Date of registration:22.05.2008
    Expiration Date:Unlimited
    The owner of the registration certificate:Alkon-Kouvreur N.V. S.A.Alkon-Kouvreur N.V. S.A. Belgium
    Manufacturer: & nbsp
    Representation: & nbspALCON PHARMACEUTICALS LTD. ALCON PHARMACEUTICALS LTD. USA
    Information update date: & nbsp28.12.2017
    Illustrated instructions
      Instructions
      Up